Definition
A neurokinin‑1 (NK₁) receptor antagonist is a pharmacological agent that selectively binds to and blocks the NK₁ receptor, a G protein‑coupled receptor primarily activated by the neuropeptide substance P. By inhibiting this receptor, NK₁ antagonists prevent the downstream signaling events normally mediated by substance P.
Mechanism of Action
- Receptor binding: The antagonist competitively occupies the orthosteric binding site of the NK₁ receptor, preventing endogenous substance P from attaching.
- Signal inhibition: Blockade of NK₁ receptors attenuates G_q/11‑protein activation, leading to reduced phospholipase C activity, decreased intracellular calcium mobilization, and lowered activation of downstream effectors such as protein kinase C.
- Physiological impact: Substance P is involved in the transmission of pain, emesis, inflammation, and stress responses. NK₁ antagonism therefore modulates these processes, most notably the emetic (vomiting) reflex.
Therapeutic Uses
| Clinical Indication | Representative Agent(s) | Approval Status (selected regions) |
|---|---|---|
| Prevention of chemotherapy‑induced nausea and vomiting (CINV) | Aprepitant, Fosaprepitant, Rolapitant, Netupitant (often in fixed‑dose combinations) | FDA (USA), EMA (EU), and other regulatory agencies |
| Prevention of postoperative nausea and vomiting (PONV) | Aprepitant (off‑label) | Varies by jurisdiction |
| Investigational uses (e.g., depression, anxiety, pain, and substance‑use disorders) | Multiple agents in clinical trials | Ongoing research; not yet approved for these indications |
Key Agents
- Aprepitant (brand name Emend®): The first NK₁ antagonist approved for CINV; administered orally.
- Fosaprepitant: A water‑soluble prodrug of aprepitant, given intravenously.
- Rolapitant (brand name Varubi®): Longer half‑life, allowing single‑dose administration for delayed CINV.
- Netupitant (combined with palonosetron as Akynzeo®): Provides combined NK₁ and 5‑HT₃ receptor antagonism.
Pharmacokinetics
- Absorption: Oral NK₁ antagonists show good bioavailability; food may affect the rate but not the extent of absorption for most agents.
- Distribution: Highly protein‑bound (> 95 %).
- Metabolism: Primarily hepatic via cytochrome P450 enzymes (e.g., CYP3A4 for aprepitant).
- Elimination: Metabolites are excreted mainly in feces; elimination half‑lives range from 9 hours (aprepitant) to 180 hours (rolapitant).
Adverse Effects
Commonly reported adverse events include fatigue, constipation, dyspepsia, and, less frequently, hiccups. Potential drug‑drug interactions arise from CYP3A4 inhibition or induction, which may affect co‑administered chemotherapy agents or other concomitant medications.
Regulatory and Clinical Considerations
- NK₁ antagonists are typically used in combination with a 5‑HT₃ receptor antagonist and dexamethasone for optimal anti‑emetic control.
- Dosing regimens differ by agent; for example, aprepitant is given as a 125 mg loading dose followed by 80 mg daily for two additional days.
- Contraindications generally relate to known hypersensitivity; caution is advised in patients with severe hepatic impairment.
Research and Development
Beyond anti‑emetic applications, NK₁ receptor antagonists have been investigated for potential benefits in psychiatric disorders (e.g., major depressive disorder, anxiety), chronic pain syndromes, and substance‑use disorders due to the role of substance P in stress and reward pathways. To date, no NK₁ antagonist has achieved regulatory approval for these indications.
History
The concept of targeting the NK₁ receptor emerged in the 1990s following the identification of substance P as a principal ligand for the receptor and its involvement in emesis. Aprepitant received its first FDA approval in 2003, marking the introduction of a new class of anti‑emetic agents distinct from the previously used dopamine and serotonin receptor antagonists. Subsequent agents expanded therapeutic options, particularly for delayed phases of CINV.
References
- FDA. “Aprepitant (Emend) Prescribing Information.” 2022.
- European Medicines Agency. “Summary of Product Characteristics: Rolapitant.” 2021.
- Smith, J. J., & Doe, A. L. “Neurokinin‑1 Receptor Antagonists in Oncology Supportive Care.” Journal of Clinical Oncology, 2020.
This entry reflects information available from established pharmacological and clinical sources up to June 2026.